




ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Review Article

The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions

1
2
3 **qi** Federico Martínón-Torres^{a,b,c,*}, José Antonio Navarro-Alonso^d, María Garcés-Sánchez^e,
4 Antoni Soriano-Arandes^f

5 ^a Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario and Universidad de Santiago de Compostela, Galicia, Spain

6 ^b Genetics, Vaccines and Paediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC),
7 Galicia, Spain

8 ^c CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

9 ^d Asociación Española de Vacunología, Madrid, Spain

10 ^e Paediatrics Service, Nazaret Health Centre, Valencia, Spain

11 ^f Paediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

ARTICLE INFO

Article history:

15 Received 14 June 2023

17 Accepted 18 June 2023

18 Available online xxx

Keywords:

21 RSV

22 Burden

23 Spain

24 Immunization

25 Prevention

26 Surveillance

ABSTRACT

The respiratory syncytial virus (RSV) causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon. RSV immunization should be in place from season 2023/2024 onwards. Doing so requires thoughtful but swift steps. This paper reflects the view of four immunization experts on the efforts being made across the globe to accommodate the new immunization options and provides recommendations organized around five priorities: (I) documenting the burden of RSV in specific populations; (II) expanding RSV diagnostic capacity in clinical practice; (III) strengthening RSV surveillance; (IV) planning for the new preventive options; (V) achieving immunization targets. Overall, Spain has been a notable example of converting RSV prevention into a national desideratum and has pioneered the inclusion of RSV in some of the regional immunization calendars for infants facing their first RSV season.

© 2023 The Author(s). Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

27
28 Discovered in 1956, the respiratory syncytial virus (RSV) is
29 a common respiratory virus that can lead to severe illness in
30 infants and young children.^{1,2} Tackling the burden of RSV has for
31 long been a global health priority. However, until recently, the
32 only approved prophylaxis for RSV was a monoclonal antibody
33 (mAb) called palivizumab. This mAb was authorized for use in the
34 European Union (EU) in 1999, for specific groups of children at
35 high-risk of RSV disease, and requires monthly injections to sustain

36 protection.^{3,4} This left many children unprotected against RSV, as
37 most cases are observed in healthy infants born at term.^{5–8}

38 After more than six decades of research, there is finally a
39 licensed immunization option that can protect the broad infant
40 population.^{9,10} In November 2022, nirsevimab was approved in
41 the EU for the prevention of RSV lower respiratory tract infections
42 (LRTI) in neonates and infants born at term or preterm during their
43 first RSV season, with or without specific health conditions, for at
44 least five months.^{3,9–16} The Food and Drug Administration (FDA)
45 Advisory Committee has also unanimously recommended nirse-
46 vimab as first immunization against RSV disease for all infants.¹⁷
47 The implementation of this new preventive strategy is expected to
48 reduce the burden of RSV-related LRTI, namely medical attention
49 and hospitalization due to RSV as well as of medically attended LRTI
50 of any cause.^{3,11,14,18–22}

51 Other active and passive immunization options, including vac-
52 cines, are in late-stage clinical development.^{3,9} The FDA has
53 recently approved two RSV vaccines for adults over 60 years old
54 and its Advisory Committee has voted in favour of the approval of
55 a maternal RSV vaccine to protect infants from severe RSV disease
56 during the first 6 months of life.^{23–27}

Abbreviations: ARI, acute respiratory infection; ECDC, European Centre for Disease Prevention and Control; EEA, European Economic Area; EU, European Union; FDA, Food and Drug Administration; HCW, health care workers; ICD, International Classification of Diseases; ICPC, International Classification of Primary Care; mAb, monoclonal antibody; LRTI, lower respiratory tract infections; RSV, respiratory syncytial virus; SARI, severe acute respiratory infection; PC, primary care; WHO, World Health Organization.

* Corresponding author.

E-mail address: Federico.Martinon.Torres@sergas.es (F. Martínón-Torres).

<https://doi.org/10.1016/j.arbres.2023.06.006>

0300-2896/© 2023 The Author(s). Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Three regions in Spain (Galicia – first place in the world to officially announce it, Catalonia and Madrid) have already confirmed the start of nirsevimab prophylaxis in all infants for the season 2023–2024. This paper reflects the view of four Spanish immunization experts on the rationale of these decisions and on the efforts being made across the globe to accommodate the new immunization options by 2023. It addresses the need for an improved RSV surveillance system and detailed data on disease burden to assist policy makers in the implementation of an RSV immunization preventive strategy. The review is conducted at a global level but provides more in-depth insights for Spain. Recommendations cover primary care (PC), hospital care, and public health perspectives.

Recommended actions

Table 1 summarizes our recommendations, organized around five areas: (I) documenting the burden of RSV in specific populations; (II) expanding RSV diagnostic capacity in clinical practice; (III) strengthening RSV surveillance; (IV) planning for the new preventive options; (V) achieving immunization targets.

I. Documenting the burden of RSV in specific populations

Having detailed data on disease burden is essential to inform resource allocation decisions for immunization policies.¹⁰ Every day, new studies are being published on the burden of RSV.^{5,28–31} Spain is not an exception. In the last two years, novelty data has been published, addressing some of the existing evidence gaps.^{5,7,32–44} We identify six areas warranting further research.

1. Estimate the burden of RSV in the outpatient and emergency room setting

While the burden of RSV hospitalizations is well characterized, it only covers the most severe cases. Furthermore, cases are often coded according to the clinical manifestations and complications from RSV conducting to hospitalisations and not recorded as associated to RSV due to lack of testing.^{45,46} Not accounting for RSV episodes managed in the outpatient setting results in an underestimated disease burden as most bronchiolitis cases are managed in PC.⁴⁷ Recent studies report that, amongst children aged < 2 years old with RSV in Spain, 95–97% visited the PC, 58–62% visited the emergency department, 28–35% were hospitalized, and at least 2% were admitted to intensive care units.^{7,38} More studies are required to fully grasp the clinical and economic burden of RSV beyond hospitalizations. Initiatives such as the RSV Hospital Emergency Departments in Iberia (RHEDI) surveillance study, built to capture the RSV burden in infants attending emergency services in the Iberian Peninsula, and the RSV ComNet, aimed to measure the clinical and socio-economic disease burden of RSV in young children in PC across countries, should be further promoted.^{5,44,48}

2. Assess the burden of RSV across all age groups

Studies tend to focus on young children, as it is where most of the burden is found. All infants are at risk of acquiring an RSV infection with severe complications, with most RSV cases being observed in children without underlying medical conditions.^{6,7,49} However, age plays an important role in the risk of developing LRTI and of being hospitalized due to RSV.⁵⁰ There is a need for a greater granularity on the patients' age reported on burden of disease studies to enable more informed decisions on immunization strategies, namely considering the months of life at the beginning of RSV season.⁵⁰ Since RSV-associated in-hospital mortality was reported to increase with age, we recommend the burden of RSV in the adult population to be

further explored as it may be underestimated, particularly in frail and high-risk older adults.^{31,39,51}

3. Quantify the burden of RSV beyond medical care

Indirect costs related to productivity losses make up a significant part of the burden of RSV, even in mild cases. A recent study in the UK estimated that RSV in children under 5 years old generated an annual cost of £80 million, with 17% attributed to productivity losses, 2% to out-of-pocket expenses for parents/carers, and 81% to direct healthcare costs.⁵²

The Respiratory Syncytial Virus Consortium in Europe (RESCEU) study, which enrolled 9164 healthy, term-born infants in five European countries (including Spain) between 2017 and 2020, found that even non-medically attended RSV episodes had a significant impact on infants.⁵ Respiratory symptoms lasted an average of 14 days in infants causing parents to miss their work duties.⁵ RSV was also associated with significant reductions in health-related quality of life for up to 14 days after diagnosis, both in children and their parents.^{38,53,54} Further research is needed to fully understand the impact of RSV on patients and caregivers, including their ability to work or study during RSV episodes.

4. Estimate the lifelong burden of RSV

It is increasingly evident that RSV infection in early childhood is associated with long-term health and economic burden.^{3,9,55–63} Children with a history of RSV LRTI are estimated to have between two to twelve times greater risk of developing asthma.^{56,62,63} Moreover, early childhood LRTI was associated with a two-fold risk of premature adult death from respiratory disease.⁶⁴ Future research is needed to understand the relationship and causality between RSV and chronic lung diseases evolution, and to measure the impact that immunization and preventive strategies may have on these long-term complications.^{55,60,61}

5. Consider the impact from preventive actions on the RSV burden

Healthy, term-born infants account for approximately 98% of RSV cases.⁶⁵ Yet, one must not forget that children with underlying medical conditions or born preterm are at higher risk of developing severe illness from an RSV infection.^{5–8} These children tend to have longer hospital stays and worse outcomes.^{5–8} It is unclear how much the use of palivizumab in at-risk groups may affect study results. As immunization against RSV becomes more prevalent, it's increasingly important for studies on the burden of RSV to incorporate the immunization context of the studied population.

6. Explore the dynamics of RSV transmission across age groups

Dynamic transmission models, paired with cost-effectiveness assessments, are expected to be valuable tools to evaluate and compare the effectiveness of alternative interventions, playing an important role when defining immunization strategies.⁶⁶ As RSV is a highly contagious pathogen, dynamic transmission models should be developed to explore if the immunization of specific populations has a protective effect on others.^{10,66–68} Population-based birth cohort studies have shown that the risk of RSV is higher in infants with older siblings, supporting vaccination strategies which include family members to offer an optimal protection for newborn babies.^{69–73} As an example, vaccination of school-aged children has been shown to diminish influenza infections in the unvaccinated adult population, as well as the number of visits and hospitalizations related to influenza.^{74–78}

Table 1
List of recommended actions.

<p><i>I. Documenting the burden of RSV in specific populations</i> Estimate the burden of RSV in the outpatient setting. Assess the burden of RSV across all age groups. Quantify the burden of RSV beyond medical care. Estimate the lifelong burden of RSV. Consider the impact from preventive actions on the RSV burden. Explore the dynamics of RSV transmission across age groups.</p> <p><i>II. Expanding RSV diagnostic capacity in clinical practice</i> Increase the awareness on the importance of testing for RSV. Increase the availability of RSV tests in PC. Establish adequate RSV case definition and diagnoses codes.</p> <p><i>III. Strengthening RSV surveillance</i> Establish RSV as a mandatory reportable disease in the EU and provide guidance for harmonized RSV surveillance. Transition to national integrated sentinel respiratory surveillance, built on robust regional surveillance systems. Integrate predictive insights from RSV surveillance with health policies for optimized system capacity and immunization planning.</p> <p><i>IV. Planning for the new preventive options</i> Publish country wide RSV prevention plans and continuously revise immunization guidance. Broaden the recommendations to also cover the adult population. Prepare the logistics for a broad immunization of infants for RSV.</p> <p><i>V. Achieving immunization targets</i> Develop educational tools to communicate the burden of RSV and the importance of immunization. Incorporate performance-based financial incentives associated to immunization targets.</p>

EU, European Union; PC, primary care; RSV, respiratory syncytial virus.

<p>170 II. Expanding RSV diagnostic capacity in clinical practice</p> <p>171 RSV testing is not yet embedded in clinical practice. This is particularly true in potential RSV cases observed outside the typical</p> <p>172 RSV season, in population aged above 6 months, and outside of the</p> <p>173 hospitals. We recommend expanding RSV diagnostic capacity, by</p> <p>174 increasing the availability of RSV tests, generating awareness on</p> <p>175 the importance of routine viral testing, and reviewing case definitions.</p> <p>176 We reckon that paediatricians might resist testing for RSV</p> <p>177 in PC, due to the prevailing belief that it will not change patient</p> <p>178 management.³²</p> <p>179</p> <p>180 7. Increase the awareness on the importance of testing for RSV</p> <p>181 There are many reasons why one should test for RSV. First, even</p> <p>182 though it remains disbelieved, knowing which respiratory virus</p> <p>183 is present enables a better patient management.^{32,79–81} Understanding</p> <p>184 the risk of disease progression can help to identify those</p> <p>185 who require a closer monitorization.^{32,82} Patients who test positive</p> <p>186 for RSV have more severe LRTI episodes than those with other</p> <p>187 respiratory viruses.^{32,38,47} Second, the viral diagnosis informs the</p> <p>188 actions to be taken to minimize the risk of transmission, which</p> <p>189 may be particularly relevant in hospitalized/institutionalized</p> <p>190 patients as respiratory infections are associated with worse clinical</p> <p>191 outcomes.^{32,83} Third, having a viral diagnosis may allow for</p> <p>192 targeted antiviral treatment, if available, and has been shown to</p> <p>193 reduce the unnecessary use of antibiotics, which is also a matter</p> <p>194 of public health concern.^{32,84,85} This need is more preminent as</p> <p>195 there are several RSV-specific antivirals in human clinical trials.⁸⁶</p> <p>196 Fourth, it helps to track epidemiologic trends when data is used</p> <p>197 by surveillance systems. Understanding the onset and offset of RSV</p> <p>198 seasons amongst regions is helpful when planning immunization</p> <p>199 and hospital admission capacity.^{32,36} The subgroup identification</p> <p>200 may also aid in healthcare planning, as RSV-A cases are associated</p> <p>201 with longer hospital stays and higher risk of requiring intensive</p> <p>202 care and respiratory support than RSV-B.⁴⁰ Finally, it may provide</p> <p>203 relevant information for physicians and families on the possible disease</p> <p>204 course and long-term sequelae, such as the risk of developing</p> <p>205 wheezing and/or asthma after RSV.^{32,87} We recommend increasing</p> <p>206 the awareness on the importance of testing for respiratory virus,</p>	<p>such as RSV, rebating the idea that it will not alter the patient management.</p> <p>8. Increase the availability of RSV tests in PC</p> <p>To the best of our knowledge, in Spain, most PC centres do not have RSV tests available, with the notable exception of Catalonia. In this region, the incorporation of rapid RSV tests in PC has led to an increase in the average age of reported RSV diagnoses, illustrating the value of routine testing to properly understand the disease burden. When choosing a test, it is important to strike a balance between accessibility, speed and accuracy.^{32,53} Antigen-based tests are not sensitive enough to be used in older children or adults.⁸⁸ However, they can still be helpful to detect epidemiologic trends and have proven to be useful for predictive models tested by surveillance systems.⁸⁹ Given their high sensitivity and specificity, we recommend that molecular-based RSV tests are used, as recommended by the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC).^{53,88,90} Furthermore, where possible, all specimens from patients with respiratory symptoms taken from primary and secondary care sentinel surveillance should be tested using multiplex PCR assays to simultaneously detect different relevant respiratory viruses.⁹⁰</p> <p>9. Establish adequate RSV case definition and diagnoses codes</p> <p>RSV surveillance requires more sensitive case definitions to avoid underestimating the disease burden. Definitions may need to vary according to age.⁹¹ There is already consensus on using acute respiratory infection (ARI) case definitions for RSV surveillance, instead of influenza-like-illness (ILI) or severe acute respiratory infection (SARI), as having fever as a criteria lowers the sensitivity for RSV case detection in young children.^{91–95} We strongly advise that other diagnoses are incorporated in RSV surveillance, such as otitis media, which is very frequently observed in infants with RSV infection.^{96–98} It is also important to revise how RSV is being coded and to establish adequate codification practices. There is evidence that RSV-specific International Classification of Diseases-10 (ICD-10) codes only capture a fraction of true RSV cases.^{45,46} Furthermore, the International Classification of Primary Care-2 (ICPC-2) does not include any code for RSV.</p>	<p>207</p> <p>208</p> <p>209</p> <p>210</p> <p>211</p> <p>212</p> <p>213</p> <p>214</p> <p>215</p> <p>216</p> <p>217</p> <p>218</p> <p>219</p> <p>220</p> <p>221</p> <p>222</p> <p>223</p> <p>224</p> <p>225</p> <p>226</p> <p>227</p> <p>228</p> <p>229</p> <p>230</p> <p>231</p> <p>232</p> <p>233</p> <p>234</p> <p>235</p> <p>236</p> <p>237</p> <p>238</p> <p>239</p> <p>240</p> <p>241</p> <p>242</p> <p>243</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




Fig. 1. Planned characteristics of integrated surveillance for RSV in EU/EEA countries, June 2022. *Note:* Figure elaborated by the authors with data collected from a survey performed, between 15 March and 9 June 2022, by the ECDC and the WHO to 29 of the 30 EU/EEA countries.¹⁰⁴ ARI, acute respiratory infection; ECDC, European Centre for Disease Prevention and Control; EU/EEA, European Union/European Economic Area; ILI, influenza-like illness; SARI, severe acute respiratory infections; WHO, World Health Organization.

Table 2

Summary of recent actions related to updated RSV prevention plans or immunization recommendations.

Country, date	Key actions	Recommended RSV immunization
CAV-AEP, ES, 2023 ¹⁰⁷	Annual calendar changed its designation to immunization calendar and included RSV.	Nirsevimab is recommended in: <ul style="list-style-type: none"> All infants younger than 6 months. Annually, in children aged < 2 years old with underlying diseases which increase the risk of a severe infection by RSV.
SP2A, FR, 2023 ¹⁰⁹	Position on bronchiolitis prevention strategies.	Nirsevimab is recommended in all infants < 1 year old and should be administered by general practitioners, paediatricians, or midwives: <ul style="list-style-type: none"> At the hospital, in infants born in season (October–March). In October, in infants born out of season.
ACIP, USA, 2023 ^{110,111}	Preliminary recommendations on mAbs for RSV prevention.	Two immunization targets are being assessed for nirsevimab: <ul style="list-style-type: none"> All infants < 8 months of age entering their first RSV season or born during the season. Children < 24 months entering their second season who remain at risk.
JCVI, UK, 2022 ^{112,120}	Nirsevimab should replace palivizumab and remain a priority for large-scale programmes.	Recommended that palivizumab is replaced by nirsevimab for the eligible cohort for the 2023/2024 RSV season. The JCVI noted that, although they were not able to make this recommendation in time for 2023/2024 season due to operational challenges, the priority is still having a ‘universal programme’. This has the support of the Department of Health and NHS.
IT, 2023 ^{113,114}	Draft 2023–2025 National Vaccination Plan includes RSV. Recommendations from scientific societies.	Universal prevention of RSV with nirsevimab should cover the entire cohort of new-borns. Administration is recommended: <ul style="list-style-type: none"> Directly at the hospital, for all children born from October to March. By the paediatrician of choice in October, in children born from April to September.
WHO, 2022 ¹⁰⁸	Published preferred product characteristics for preventive RSV mAb.	Preferences for RSV mAb include being targeted to all infants in the first 6 months of life, with one-dose regimen given at birth or at any healthcare visit during the first 6 months of life.
Vaccines together, 2022 ⁹	Paper with experts’ recommendations.	Nirsevimab is recommended for infants, especially in the first six months, and should be considered also for children aged under 5 years as main transmitting agents.

ACIP, Advisory Committee on Immunization Practices; CAV-AEP, *Comité Asesor de Vacunas de la Asociación Española de Pediatría*; ES, Spain; FR, France; IT, Italy; JCVI, Joint Committee on Vaccination and Immunization; mAb, monoclonal antibody; RSV, respiratory syncytial virus; SP2A, *Société pédiatrique de pneumologie et d’allergologie*; UK, United Kingdom; USA, United States of America; WHO, World Health Organization.

^a Published preferred product characteristics for long-acting RSV mAb include being: (i) indicated for the prevention of severe RSV disease during early infancy, as it is the period of highest risk of severe RSV disease and mortality; (ii) targeted to all infants in the first 6 months of life; (iii) administered with a one-dose regimen, that could be given as a birth dose or at any healthcare visit during the first 6 months of life; (iv) comparable with WHO recommended vaccines given at the same age in terms of safety and reactogenicity; (v) effective against RSV-confirmed severe disease for five months following administration ($\geq 70\%$ efficacy); (vi) able to protect against both RSV A and B subtypes; (vii) administered as a single intramuscular or subcutaneous dose using standard volumes for injection; (viii) accessible and affordable to low- and middle-income countries in order to allow broad protection of the most vulnerable infants; amongst other criteria.¹⁰⁸

III. Strengthening RSV surveillance

Up until recently, most countries detected RSV infections within existing surveillance systems for influenza.⁹¹ With the advent of new immunization solutions, and with the COVID-19 pandemic acting as a catalyst, an international movement is underway to improve RSV surveillance. Anticipating this moment, the WHO has been piloting globally compatible RSV-

disease-burden surveillance systems.^{91,99–101} The goal is to have RSV embedded in national surveillance programmes in 2023, by transitioning to end-to-end integrated sentinel surveillance of influenza, SARS-CoV-2 and RSV.⁹⁹ Molecular surveillance is essential to monitor the geotemporal evolution of RSV strains and enable early detection of potential escape variants that can impact RSV transmission and the effectiveness of immunization.^{102,103}

10. Establish RSV as a mandatory reportable disease in the EU and providing guidance for harmonized RSV surveillance

Although RSV is not yet a mandatory reportable disease in the European Union/European Economic Area (EU/EEA) level, in 2022, twelve EU/EEA countries had already made RSV a notifiable disease.¹⁰⁴ We are in favour of adding RSV to the list of mandatory notifiable diseases at the EU level, to allow EU-wide data analysis. Guidance for a harmonized RSV surveillance within the EU would also be welcomed.

11. Transition to national integrated sentinel respiratory surveillance, built on robust regional surveillance systems

Most of the EU/EEA countries foresee including respiratory viruses other than influenza and SARS-CoV-2, such as RSV, in their surveillance systems.¹⁰⁴ In 2022, twelve countries had already started transitioning to integrated sentinel respiratory surveillance, as illustrated in Fig. 1. In Spain, the previous influenza surveillance system was modified in 2021 to incorporate the surveillance of acute respiratory infections – including influenza, COVID-19, and RSV – and is now called *Sistema de Vigilancia de la Infección Respiratoria Aguda* (SiVIRA). This all-year surveillance will integrate data from PC, hospitals, microbiology, and genomic laboratories. We commend this transition but underline the importance of building the national surveillance system on cohesive and robust regional surveillance systems.

12. Integrate predictive insights from RSV surveillance with health policies related to healthcare system capacity readiness and RSV immunization

In Spain, Catalonia was the first region integrating the functions of epidemiological surveillance of influenza, COVID-19, RSV and other respiratory viruses.¹⁰⁵ The developed system presents a set of unique characteristics, detailed in [Supplementary Materials \(Table S1\)](#). A splendid example is the linkage of RSV surveillance data with public health policies. Catalonia intends to achieve better capacity planning by using surveillance data from PC to anticipate RSV hospitalization peaks within a 2–3-week window.⁸⁹ We see a great added value in this approach, and recommend incorporating similar predictive models in the national surveillance systems. Incorporating near real-time accurate data from different regions would enable a greater anticipation of RSV outbreaks. This could help to prepare spaces for the predicted increased demand for care. It can also facilitate the implementation of immunization strategies.

IV. Planning for the new preventive options

No innovation adds value unless it reaches the population that will benefit from it. RSV prevention is rapidly entering the political agendas, with scientific associations and policy makers joining efforts to make immunization available. Experts are reviewing the most adequate preventive option and strategies to each population group, to maximize the impact of immunization in public health. Regulatory bodies need to incorporate these new interventions in their evaluation processes and to provide guidance on how they will be funded and implemented at national and regional level.¹⁰⁶

13. Publish country wide RSV prevention plans and continuously revise immunization guidance

[Table 2](#) summarizes recent updates in RSV prevention plans or immunization recommendations from several countries. We applaud the efforts from the international community and the

example set by Spain, who has turned RSV prevention into a national desideratum, and three regions have pioneered the inclusion of RSV in the immunization calendars for infants facing their first RSV season.¹⁰⁷

Important moves include the WHO international standards for RSV vaccines and mAb, to harmonize their evaluation, and national guidelines for the RSV immunization, in terms of target population, place and timing of administration, amongst others.^{9,107–114} The extent to which these recommendations may need to be revised in the future will depend on factors such as the duration of the protection provided by the mAbs or vaccines and its long-term efficacy and safety, but also on the evaluation of potential additional benefits associated to the reduction in the use of antibiotics and of medically attended LRTI of any cause. Results should be continuously assessed to determine the optimal frequency of immunization.

14. Broaden the recommendations to also cover the adult population

We advocate for scientific societies to publish guidance also for the immunization of the adult population. Medical societies treating patients with comorbidities should be involved in the elaboration of these guidelines, but we consider that immunization recommendations will more successful if they are based on age groups instead of specific medical conditions.

15. Prepare the logistics for a broad immunization of infants for RSV

To achieve a broad immunization of infants in time for the RSV season, proper structures must be in place, including processes for the administration and data reporting in all health centres, and sufficient and on-time product stock. Overall, we consider that the logistics will be less challenging in countries such as Spain, who have a good culture of vaccination and a close follow-up of infants through the public PC system. This enables both immunization at the hospital or in one of the programmed follow-up consultations after birth. If a long-lasting effect of RSV immunization is shown in adults, we would advise that the administration is performed throughout the year to reach more people.

V. Achieving immunization targets

Finally, we would like to stress the importance of generating awareness on the burden of RSV and benefits of immunization, and of certifying that there are incentives in place that capture the urgency to achieve immunization targets.

16. Develop educational tools to communicate the burden of RSV and the importance of immunization

In Spain, we do not anticipate barriers from paediatricians in the immunization for RSV as there is already a strong culture of vaccination. Challenges are expected to be encountered in general practitioners and other medical specialties, who may be less aware of the impact of RSV, and, in adults, due to the less rooted culture of vaccination and the lack of awareness regarding RSV infection in countries where culture of vaccination is less present for respiratory infections.¹¹⁵ We recommend developing campaigns and educational tools for parents and clinicians focused on spreading the message that RSV affects people of all ages and that risk of infection can, and should, be mitigated. For us, the best spokespersons will be parents of children that were hospitalised with RSV during infancy.¹¹⁶ Patients' associations have an important role in generating awareness and should be promoted. A good example is the RSV

374 Patient Network founded in 2016 by the RESCEU Patient Advisory
375 Board.¹¹⁷

376 17. Incorporate performance-based financial incentives associated
377 to immunization targets

378 Immunization is critical to fight respiratory infections and high
379 coverage rates are likely only feasible with the involvement of
380 PC health care workers (HCW). We recommend incorporating
381 performance-based financial incentives to PC HCW as a policy
382 instrument to increase coverage rates, as performed in other
383 European countries for vaccines against influenza and SARS-CoV-
384 2.^{118,119}

385 Conclusions

386 Reducing the burden of RSV is a public health priority. Coun-
387 tries should target to have RSV immunization in place from season
388 2023/2024 onwards. Doing so requires thoughtful but swift steps.
389 This paper aims to contribute to this great effort, by recommending
390 seventeen actions organized around five priority areas.

391 Authors' contributions

392 All authors have equally contributed to the redaction and revision
393 of the manuscript. The views reflected in this publication are
394 personal and do not necessarily reflect the views of the institutions
395 to which the authors are affiliated.

396 Ethics approval and consent to participate

397 N/A.

398 Consent for publication

399 N/A.

400 Funding

401 Sanofi has funded the medical writing and editorial support of
402 this manuscript. The authors were not paid for writing the publi-
403 cation.

404 Conflict of interest

405 Sanofi has funded the medical writing and editorial support of
406 this manuscript. The authors were not paid for writing the publi-
407 cation.

408 FMT received honoraria from GSK group of companies, Pfizer
409 Inc, Sanofi Pasteur, MSD, Seqirus, and Janssen for taking part in
410 advisory boards and expert meetings and for acting as a speaker
411 in congresses outside the scope of the submitted work. FMT has
412 also acted as principal investigator in randomized controlled tri-
413 als of the above-mentioned companies as well as Ablynx, Gilead,
414 Regeneron, Roche, Abbott, Novavax, and MedImmune, with hon-
415 oraria paid to his institution. AS-A, JANA and MG have nothing to
416 declare regarding this manuscript.

417 Acknowledgements

418 The authors would like to thank Mafalda Carmo (IQVIA,
419 Barcelona, Spain) and Carmen Barrull (IQVIA, Barcelona, Spain) for
420 medical writing and editorial assistance.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in
the online version, at [doi:10.1016/j.arbres.2023.06.006](https://doi.org/10.1016/j.arbres.2023.06.006).

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2095–128.
2. Junge S, Nokes DJ, Simões EAF, Weber MW. Respiratory syncytial virus. In: *International encyclopedia of public health*. Elsevier; 2008. p. 561–71. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780123739605006213> [cited 19.3.23].
3. Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M, et al. RSV prevention in all infants: which is the most preferable strategy? *Front Immunol*. 2022;880368.
4. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. *Antimicrob Agents Chemother*. 2012;56:4927–36.
5. Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. *Lancet Respir Med*. 2022. S2213260022004143.
6. Bandeira T, Carmo M, Lopes H, Gomes C, Martins M, Guzman C, et al. Burden and severity of children's hospitalizations by respiratory syncytial virus in Portugal, 2015–2018. *Influenza Resp Viruses*. 2023;17. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/irv.13066> [cited 20.3.23].
7. Martínón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. *BMC Infect Dis*. 2022;22:759.
8. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med*. 2009;360:588–98.
9. Bont L, Weil Olivier C, Herting E, Esposito S, Navarro Alonso JA, Lega F, et al. The assessment of future RSV immunizations: how to protect all infants? *Front Pediatr*. 2022;10:9817–41.
10. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. *Vaccine*. 2013;31:B209–15.
11. Bergeron HC, Tripp RA. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). *Exp Opin Invest Drugs*. 2022;31:23–9.
12. Pinquier D, Crépey P, Tissières P, Vabret A, Roze JC, Dubos F, et al. Preventing respiratory syncytial virus in children in France: a narrative review of the importance of a reinforced partnership between parents, healthcare professionals, and public health authorities. *Infect Dis Ther*. 2023;12:317–32.
13. Reina J, Iglesias C, Nirsevimab: Towards universal child immunization against respiratory syncytial virus. *Vacunas (Engl Ed)*. 2023;24:68–73.
14. Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. *Lancet Child Adolesc Health*. 2023;7:180–9.
15. European Medicines Agency. Beyfortus (nirsevimab): An overview of Beyfortus and why it is authorised in the EU. EMA/776857/2022. [Internet]. 2022. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus>.
16. Keam SJ. Nirsevimab: first approval. *Drugs*. 2023;83:181–7.
17. Sanofi. Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants [Internet]. 2023. Available from: <https://www.sanofi.com/en/media-room/press-releases/2023/2023-06-08-21-19-00-2685235>.
18. Jorgensen SCJ. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. *J Antimicrob Chemother*. 2023;dkad076.
19. Griffin MP, Yuan Y, Takas T, Domachowski JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. *N Engl J Med*. 2020;383:415–25.
20. Hammit LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. *N Engl J Med*. 2022;386:837–46.
21. Kieffer et al. In: Specificities and commonalities of RSV disease burden in US, France, UK and Spain, and expected modelled impact of nirsevimab. Lisbon, Portugal: RSVVW'23 7th ReSViNET Conference; 2023.
22. Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. *N Engl J Med*. 2023;388:1533–4.
23. Pfizer. Press release: U.S. FDA accepts biologics license application for Pfizer's respiratory syncytial virus maternal vaccine candidate for priority review. 2023. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-biologics-license-application-pfizers>.

24. U.S. Food and Drug Administration. FDA approves first respiratory syncytial virus (RSV) vaccine [Internet]. 2023. (FDA News release). Available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine>.
25. European Medicines Agency. Arexvy, respiratory syncytial virus vaccine (recombinant, adjuvanted) summary of opinion EMA/CHMP/141401/2023 [Internet]. 2023. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-arexvy_en.pdf.
26. Pfizer. Press release: U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults. 2023. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention>.
27. Pfizer. FDA advisory committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization. 2023. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/fda-advisory-committee-votes-support-approval-pfizers>.
28. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022;399(10340):2047–64.
29. Raes M, Daelemans S, Cornette L, Moniotte S, Proesmans M, Schaballie H, et al. The burden and surveillance of RSV disease in young children in Belgium—expert opinion. *Eur J Pediatr*. 2022;182:451–60.
30. Del Riccio M, Spreuvenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV, Teirlinck AC, et al. Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. *Respir Med*. 2023. Available from: <http://medrxiv.org/lookup/doi/10.1101/2023.02.10.23285756> [cited 20.3.23].
31. Savic M, Penders Y, Shi T, Branche A, Pirçon J. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. *Influenza Resp Viruses*. 2023;17. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/irv.13031> [cited 20.3.23].
32. Mejias A, Sanchez-Codez MI, Ramilo O, Sanchez PJ. The importance of viral testing in infants and young children with bronchiolitis. *J Pediatr*. 2022;98:326–8.
33. Heppes-Montero M, Walter S, Hernández-Barrera V, Gil-Prieto R, Gil-de-Miguel Á. Burden of respiratory syncytial virus-associated lower respiratory infections in children in Spain from 2012 to 2018. *BMC Infect Dis*. 2022;22:315.
34. Heppes-Montero M, Gil-Prieto R, Walter S, Alexandre Blanquer F, Gil De Miguel Á. Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. *Hum Vac Immunotherap*. 2022;18:1883379.
35. Vila J, Lera E, Andrés C, Piñana M, Rello-Saltor V, Tobeña-Rué M, et al. The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): a long-term, clinical, epidemiological and economic study. *Influenza Resp Viruses*. 2023;17. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/irv.13085> [cited 20.3.23].
36. Coma E, Vila J, Méndez-Boo L, Antón A, Mora N, Fina F, et al. Respiratory syncytial virus infections in young children presenting to primary care in Catalonia during the COVID-19 pandemic. *J Pediatr Infect Dis Soc*. 2022;11:69–72.
37. Mira-Iglesias A, Demont C, López-Labrador FX, Mengual-Chuliá B, García-Rubio J, Carballido-Fernández M, et al. Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain. *Influenza Resp Viruses*. 2022;16:328–39.
38. Díez-Gandía E, Gómez-Álvarez C, López-Lacort M, Muñoz-Quiles C, Úbeda-Sansano I, Díez-Domingo J, et al. The impact of childhood RSV infection on children's and parents' quality of life: a prospective multicenter study in Spain. *BMC Infect Dis*. 2021;21:924.
39. Heppes-Montero M, Gil-Prieto R, del Diego Salas J, Hernández-Barrera V, Gil-de-Miguel Á. Impact of respiratory syncytial virus and influenza virus infection in the adult population in Spain between 2012 and 2020. *IJERPH*. 2022;19:14680.
40. Vila J, Lera E, Peremiquel-Trillas P, Andrés C, Martínez L, Barceló I, et al. Increased RSV-A bronchiolitis severity in RSV-infected children admitted to a reference center in Catalonia (Spain) between 2014 and 2018. *J Pediatr Infect Dis Soc*. 2023;piad009.
41. González-Granado LI, Martín-Nalda A, Alsina L, Neth O, Santamaría M, Soler-Palacín P. Respiratory syncytial virus infections requiring hospitalization in patients with primary immunodeficiency. *Anal Pediatr (Engl Ed)*. 2022;96:492–500.
42. Rodríguez-Fernandez R, González-Sánchez MI, Perez-Moreno J, González-Martínez F, de la Mata Navazo S, Mejias A, et al. Age and respiratory syncytial virus etiology in bronchiolitis clinical outcomes. *J Allergy Clin Immunol Global*. 2022;1:91–8.
43. Piñana et al. In: Surveillance and evolution of human respiratory syncytial virus by whole genome sequencing during the 2013–2022 seasons in Barcelona, Spain. Lisbon, Portugal: RSVVV'23 7th ReSViNET Conference; 2023.
44. Dacosta-Urbieta et al. In: RSV burden in infants attending hospital emergency departments in Iberia. The RHEDI study. Lisbon, Portugal: RSVVV'23 7th ReSViNET Conference; 2023.
45. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. *Influenza Other Resp Viruses*. 2020;14:630–7.
46. Hamilton MA, Calzavara A, Emerson SD, Djebli M, Sundaram ME, Chan AK, et al. Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. *PLOS ONE*. 2021;16:e0244746.
47. Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, et al. Population-based analysis of bronchiolitis epidemiology in Valencia, Spain. *Pediatr Infect Dis J*. 2016;35:275–80.
48. Hoang U, Button E, Armstrong M, Okusi C, Ellis J, Zambon M, et al. Assessing the clinical and socioeconomic burden of respiratory syncytial virus in children aged under 5 years in primary care: protocol for a prospective cohort study in England and report on the adaptations of the study to the COVID-19 pandemic. *JMIR Res Protoc*. 2022;11:e38026.
49. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. *PLOS ONE*. 2014;9:e89186.
50. Sommer C. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. *TOMICROJ*. 2011;5:144–54.
51. Van Effelther T, Hens N, White LJ, Gravenstein S, Bastian AR, Buyukkaramikli N, et al. Modeling respiratory syncytial virus adult vaccination in the United States with a dynamic transmission model. *Clin Infect Dis*. 2023:ciad161.
52. Fusco F, Hocking L, Stockwell S, Bonsu M, Marjanovic S, Morris S, et al. The burden of respiratory syncytial virus: understanding impacts on the NHS, society and economy. *Rand Health Q*. 2022;10:2.
53. Zuurbier RP, Korsten K, Verheij TJM, Butler C, Adriaenssens N, Coenen S, et al. Performance assessment of a rapid molecular respiratory syncytial virus point-of-care test: a prospective community study in older adults. *J Infect Dis*. 2022;226 Suppl. 1:S63–70.
54. Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. *Vaccine*. 2023;41:2707–15.
55. Fauroux B, Simões EAF, Checchia PA, Paes B, Figueras-Aloy J, Manzoni P, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. *Infect Dis Ther*. 2017;6:173–97.
56. Baraldi E, Bonadies L, Manzoni P. Evidence on the link between respiratory syncytial virus infection in early life and chronic obstructive lung diseases. *Am J Perinatol*. 2020;37(S 02):S26–30.
57. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. *Am J Respir Crit Care Med*. 2015;191:34–44.
58. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med*. 2013;368:1791–9.
59. Chirikov V, Botteman M, Simões EA. The long-term healthcare utilization and economic burden of RSV infection in children ≤5 years in Japan: propensity score matched cohort study. *CEOR*. 2022;14:699–714.
60. Carraro S, Scheltema N, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. *Eur Respir J*. 2014;44:1682–96.
61. Grant T, Brigham EP, McCormack MC. Childhood origins of adult lung disease as opportunities for prevention. *J Allergy Clin Immunol Pract*. 2020;8:849–58.
62. Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. *Lancet*. 2023. S01406736230008115.
63. Billard MN, Bont LJ. The link between respiratory syncytial virus infection during infancy and asthma during childhood. *Lancet*. 2023. S01406736230006724.
64. Allinson JP, Chaturvedi N, Wong A, Shah I, Donaldson GC, Wedzicha JA, et al. Early childhood lower respiratory tract infection and premature adult death from respiratory disease in Great Britain: a national birth cohort study. *Lancet*. 2023. S0140673623001319.
65. Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004–2012. *Curr Med Res Opin*. 2016;32:693–8.
66. Lang JC. Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review. *J Math Biol*. 2022;84:26.
67. Kombe IK, Munywoki PK, Baguelin M, Nokes DJ, Medley GF. Model-based estimates of transmission of respiratory syncytial virus within households. *Epidemics*. 2019;27:1–11.
68. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. *Infect Dis Ther*. 2016;5:271–98.
69. Jacoby P, Glass K, Moore HC. Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study. *Epidemiol Infect*. 2017;145:266–71.
70. Otomaru H, Kamigaki T, Tamaki R, Okamoto M, Alday PP, Tan AG, et al. Transmission of respiratory syncytial virus among children under 5 years in households of rural communities, the Philippines. *Open Forum Infect Dis*. 2019;6:ofz045.
71. Munywoki PK, Koeh DC, Agoti CN, Lewa C, Cane PA, Medley GF, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. *J Infect Dis*. 2014;209:1685–92.
72. Munywoki PK, Koeh DC, Agoti CN, Bett A, Cane PA, Medley GF, et al. Frequent asymptomatic respiratory syncytial virus infections during an epidemic in a rural Kenyan household cohort. *J Infect Dis*. 2015;212:1711–8.
73. Munywoki PK, Koeh DC, Agoti CN, Cane PA, Medley GF, Nokes DJ. Continuous invasion by respiratory viruses observed in rural households during a

- respiratory syncytial virus seasonal outbreak in coastal Kenya. *Clin Infect Dis*. 2018;67:1559–67.
74. Nayak J, Hoy G, Gordon A. Influenza in children. *Cold Spring Harb Perspect Med*. 2021;11:a038430.
75. Weycker D, Edelsberg J, Elizabeth Halloran M, Longini IM, Nizam A, Ciuryla V, et al. Population-wide benefits of routine vaccination of children against influenza. *Vaccine*. 2005;23:1284–93.
76. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. *PLOS Med*. 2013;10:e1001527.
77. Pebody RG, Sinnathamby MA, Warburton F, Andrews N, Boddington NL, Zhao H, et al. Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. *Eurosurveillance*. 2018;23. Available from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.25.1700496> [cited 20.3.23].
78. Wang B, Russell ML, Moss L, Fonseca K, Earn DJD, Aoki F, et al. Effect of influenza vaccination of children on infection rate in hutterite communities: follow-up study of a randomized trial. *PLOS ONE*. 2016;11:e0167281.
79. Ralston SL, Lieberthal AS, Meissner HC, Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014;134:e1474–502. *Pediatrics*. 2015 Oct;136(4):782.
80. Mejias A, Dimo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jartti T, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. *PLOS Med*. 2013;10:e1001549.
81. Troy NM, Bosco A. Respiratory viral infections and host responses; insights from genomics. *Respir Res*. 2016;17:156.
82. McGeoch LJ, Thornton HV, Blair PS, Christensen H, Turner NL, Muir P, et al. Prognostic value of upper respiratory tract microbes in children presenting to primary care with respiratory infections: a prospective cohort study. *PLOS ONE*. 2022;17:e0268131.
83. Simon A, Müller A, Khurana K, Engelhart S, Exner M, Schildgen O, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection – results from a prospective multicenter German surveillance study. *Int J Hyg Environ Health*. 2008;211(3–4):241–50.
84. Ferronato ÂE, Gilio AE, Ferraro AA, de Paulis M, Vieira SE. Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis. *Clinics*. 2012;67:1001–6.
85. Domachowski JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment [Internet]. *Adis J*; 2021. p. 140789 Bytes. Available from: https://adisjournals.figshare.com/articles/figure/The_Future_of_Respiratory_Syncytial_Virus_Disease_Prevention_and_Treatment/13333481 [cited 15.3.23].
86. Martínón-Torres F, Rusch S, Huntjens D, Remmerie B, Vingerhoets J, McFadyen K, et al. Pharmacokinetics, safety, and antiviral effects of multiple doses of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: a randomized phase 1b study. *Clin Infect Dis*. 2020;71:e594–603.
87. Cabral C, Ingram J, Hay AD, Horwood J. “They just say everything’s a virus” – parent’s judgment of the credibility of clinician communication in primary care consultations for respiratory tract infections in children: a qualitative study. *Patient Educ Counsel*. 2014;95:248–53.
88. Bernstein DI, Mejias A, Rath B, Woods CW, Deeter JP. Summarizing study characteristics and diagnostic performance of commercially available tests for respiratory syncytial virus: a scoping literature review in the COVID-19 era. *J Appl Lab Med*. 2023;8:353–71.
89. Perramon-Malavez et al. In: *Epidemiological characterization and modelling for short-term prediction of bronchiolitis in Catalonia, Spain*. Lisbon, Portugal: RSVVV’23 7th ReSViNET Conference; 2023.
90. World Health Organization. Operational considerations for respiratory virus surveillance in Europe [Internet]. No. WHO/EURO: 2022-5841-45606-65427. World Health Organization. Regional Office for Europe; 2022. Available from: <https://apps.who.int/iris/handle/10665/360349>.
91. Sáez-López E, Pechirra P, Costa I, Cristóvão P, Conde P, Machado A, et al. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010–2018. *Eurosurveillance*. 2019;24. Available from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.45.1900140> [cited 19.3.23].
92. Rha B, Dahl RM, Moyes J, Binder AM, Tempia S, Walaza S, et al. Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness—South Africa, 2009–2014. *J Pediatr Infect Dis Soc*. 2019;8:325–33.
93. Klink T, Rankin DA, Piya B, Spieker AJ, Faouri S, Shehabi A, et al. Evaluating the diagnostic accuracy of the WHO Severe Acute Respiratory Infection (SARI) criteria in Middle Eastern children under two years over three respiratory seasons. *PLOS ONE*. 2020;15:e0232188.
94. Hirve S, Crawford N, Palekar R, Zhang W, the WHO RSV surveillance Group, Bancej C, et al. Clinical characteristics, predictors, and performance of case definition—interim results from the WHO global respiratory syncytial virus surveillance pilot. *Influenza Other Respi Viruses*. 2020;14:647–57.
95. von Eije KJ, Organization WH. Maintaining surveillance of influenza and monitoring SARS-CoV-2: adapting Global Influenza Surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic: interim guidance. 2020.
96. Thomas E, Mattila JM, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of respiratory syncytial virus infection during the first year of life. *J Infect Dis*. 2021;223:811–7.
97. Teirlinck AC, Broberg EK, Stuwitz Berg A, Campbell H, Reeves RM, Carnahan A, et al. Recommendations for respiratory syncytial virus surveillance at the national level. *Eur Respir J*. 2021;58:2003766.
98. Bulut Y, Güven M, Otlu B, Yenisehirli G, Aladağ İ, Eyibilen A, et al. Acute otitis media and respiratory viruses. *Eur J Pediatr*. 2007;166:223–8.
99. WHO. Strategy for the global respiratory syncytial virus surveillance based on influenza surveillance [Internet]. Geneva, Switzerland: World Health Organization; 2019. Available from: https://cdn.who.int/media/docs/default-source/influenza/rsv-surveillance/who-rsv-surveillance-strategy-phase-26mar2021-final.pdf?sfvrsn=d8b1c36a_9&sua=1.
100. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a world health organization meeting held on 23–24 March 2015. *Vaccine*. 2016;34:190–7.
101. World Health Organization. Progress and future directions of WHO respiratory syncytial virus surveillance – report from the WHO meeting in November 2022. *World Health Organ*. 2023;98:159–63.
102. Wilkins D, Langedijk AC, Lebbink RJ, Morehouse C, Abram ME, Ahani B, et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. *Lancet Infect Dis*. 2023. S1473309923000622.
103. Tabor DE, Fernandes F, Langedijk AC, Wilkins D, Lebbink RJ, Tovchigrechko A, et al. Global molecular epidemiology of respiratory syncytial virus from the 2017–2018 INFORM-RSV study. *J Clin Microbiol*. 2020;59, e01828–20.
104. ECDC/WHO. Survey on the implementation of integrated surveillance of respiratory viruses with pandemic potential. Survey results from 29 European Union/European Economic Area (EU/EEA) countries [Internet]. ECDC/WHO; 2022. Available from: <https://www.ecdc.europa.eu/en/publications-data/survey-implementation-integrated-surveillance-respiratory-viruses-pandemic>.
105. Health Information System for Surveillance of Infections in Catalonia [Internet]. Gencat; 2022. Available from: <https://sivic.salut.gencat.cat/documentacio>.
106. National Foundation for Infectious Diseases. Call to action: reducing the burden of RSV across the lifespan [Internet]. National Foundation for Infectious Diseases; 2021. Available from: <https://www.nfid.org/publications/call-to-action-reducing-the-burden-of-rsv-across-the-lifespan/>.
107. Álvarez García FJ, Cilleruelo Ortega MJ, Álvarez Aldeán J, Garcés-Sánchez M, Garrote Llanos E, Iofrio de Arce A, et al. Calendario de inmunizaciones de la Asociación Española de Pediatría: recomendaciones 2023. *Anal Pediatr*. 2023;98:e1–10.
108. Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, et al. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – key considerations for global use. *Vaccine*. 2022;40:3506–10.
109. SP2A (2023). Position de la SP2A sur les stratégies de prévention de la bronchiolite 26/01/2023.
110. Working group on RSV prevention. Observations – challenges – strategies. Draft report. 6th Life Course Immunisation Summit 2021–2022.
111. Jones. Next steps for the ACIP maternal & pediatric RSV work group. ACIP General Meeting October 20, 2022.
112. Joint committee on vaccination and immunisation. Minute of the meeting held on 19 October 2022. Held in Nobel House, Smith Square, London, and by teleconference.
113. Piano Nazionale Prevenzione Vaccinale PNPV 2023–2025, 30 December 2022.
114. Board del Calendario per la Vita. Posizione del Board del Calendario Vaccinale per la Vita e della Società Italiana di Neonatologia sul possibile utilizzo di anticorpi monoclonali a lunga emivita per la prevenzione universale delle malattie da Virus Respiratorio Sinciziale (VRS o RSV) nel neonato [Internet]. 2023. Available from: <http://www.igienistonline.it/docs/2023/03pp.pdf>.
115. Schaffner W. Reducing the burden of respiratory syncytial virus across the lifespan. *Infect Dis Clin Pract*. 2023;31:e1210.
116. Campbell A, Hartling L, Louie-Poon S, Scott SD. Parent experiences caring for a child with bronchiolitis: a qualitative study. *J Patient Exp*. 2020;7:1362–8.
117. RESCEU. About RSV patient network. Available from: <https://resceu.org/parents-patients/rsv/about-rsv-patient-network/>.
118. Milstein R, Shatrov K, Schmutz LM, Blankart CR. How to pay primary care physicians for SARS-CoV-2 vaccinations: an analysis of 43 EU and OECD countries. *Health Policy*. 2022;126:485–92.
119. Liaqat A, Gallier S, Reeves K, Crothers H, Evison F, Schmidtke K, et al. Examining organisational responses to performance-based financial incentive systems: a case study using NHS staff influenza vaccination rates from 2012/2013 to 2019/2020. *BMJ Qual Saf*. 2022;31:642.
120. Joint Committee on Vaccination and Immunisation P. Minute of the meeting held on 01 February 2023 [Internet]. 2023. Available from: <https://app.box.com/s/iddfb4ppwkmjtjusr2tc/file/1165597788909> [cited 15.3.23].